Not published trials, both recruiting and not recruiting, targeting MAPK pathway
| NCT | Phase | Status | Tumors | Line of treatment | Target | Experimental treatment | Standard treatment | Primary endpoints | Sponsor |
|---|---|---|---|---|---|---|---|---|---|
| NCT00397384 | 1 | Completed | eCCA | Non specified | KRAS wild type | Erlotinib + Cetuximab | N.A. | MTD | No-profit |
| NCT04190628 | 1 | Recruiting | CCA | NTA | BRAF V600 mutation | ABM-1310 | N.A. | MTD/RP2D | Profit |
| NCT04566133 | 1 | Not yet recruiting | CCA | NTA | KRAS mutation | Trametinib + HCQ | N.A. | PFS | Profit |
HCQ: hydroxychloroquine